Marty Simonetti

Abeome Corp. operates as a biotechnology company. It develops therapeutic and diagnostic monoclonal antibodies (mAbs). The firm’s DiSH (Direct Selection of Hybridomas) technology offers a process for selecting and cloning desired hybridomas that produce antibodies with optimal binding characteristics. The company was founded by Richard B. Meagher in 2000 and is headquartered in Athens, GA.

Abeome Corp. operates as a biotechnology company. It develops therapeutic and diagnostic monoclonal antibodies (mAbs). The firm’s DiSH (Direct Selection of Hybridomas) technology offers a process for selecting and cloning desired hybridomas that produce antibodies with optimal binding characteristics. The company was founded by Richard B. Meagher in 2000 and is headquartered in Athens, GA.

Abeome Corp. operates as a biotechnology company. It develops therapeutic and diagnostic monoclonal antibodies (mAbs). The firm’s DiSH (Direct Selection of Hybridomas) technology offers a process for selecting and cloning desired hybridomas that produce antibodies with optimal binding characteristics. The company was founded by Richard B. Meagher in 2000 and is headquartered in Athens, GA.

Abeome Corp. operates as a biotechnology company. It develops therapeutic and diagnostic monoclonal antibodies (mAbs). The firm’s DiSH (Direct Selection of Hybridomas) technology offers a process for selecting and cloning desired hybridomas that produce antibodies with optimal binding characteristics. The company was founded by Richard B. Meagher in 2000 and is headquartered in Athens, GA.